Company / Operating Margin
Vivos Therapeutics, Inc. Operating Margin History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-74.3%
FY2025
5-year range
-156.2% / -74.3%
FY2021-FY2025
Trend
+40.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -156.2% to -74.3% over the past 2 years.
Based on SEC 10-K filings.
-74.3% in FY2025 with a 5-year CAGR of +18.5%.
Improved from -156.2% to -74.3% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- +46.4pp
- 5-Year Change
- +18.5pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, operating margin increased 40.7% year-over-year.
- Lowest operating margin in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -74.3% | +40.7% |
| FY2024 | -125.3% | +19.8% |
| FY2023 | -156.2% | -29.4% |
| FY2022 | -120.7% | -31.0% |
| FY2021 | -92.2% | +0.7% |
| FY2020 | -92.8% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026